The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Can see us all making some serious money here.
Todays contract win, working with the JV within SSE renewables, Equinor and Vargronn. 3 of the biggest players in the offshore renewable space.
£1 is only £61m penny’s to these monster energy companies. The tech ( cables ) has been patented according to RNS from awhile back. Could go crazy very quickly here
GLA
DSFLAT
My thinking exactly. Personally think we see £1 here in the short term
Any sniff of a buyout to a big company and this will fly.
61m shares in issue,
Tiny mcap
Orders worth over £20m
Another contract today for 130km or offshore cables
Offshore wind farms are going to be massive for renewables
June £20m in orders on the books for first 6 months of the year. And todays contract win. Very positive
HL showing BID STITUATION. hopefully RNS soon
Stop loss hunt didn’t work. Down to 11.50 and straight back up. Strong finish on the cards
25 days or so to wait
Could see a real push between now and 12.30 with people wanting in.
Someone buy in the background in numbers
I have been buying. Getting offered buy price to sell on a dummy
Sadly Budd will not give two f*cks about any emails sent to him. I agree he has to go. Sadly I don’t think he will.
GLA
Genflow research partner has been very busy! A very positive read this. A lot going on behind the scenes
A Project by Biotech Entrepreneur Ethan Perlstein & Magnitude
Background
One of the greatest challenges for biomedical sciences is how to slow ageing. Ageing is the major risk factor for almost all chronic diseases. And it has been estimated that one extra year of working life would increase UK GDP by 1%. Ethan Perlstein and others found that a small molecule called SMER28 was an inducer of autophagy. This earlier research used a multi-species approach to drug discovery that started with a yeast chemical modifier screen and was followed by studies in flies and human cells to further understand the mechanism of action. Subsequently, SMER28 was shown to improve models of anemia in human hematopoietic stem cells, zebrafish and mice. However, there was no known effect on Healthspan, and the target remained unknown.
Ethan identified the contract research organisation Magnitude Biosciences to investigate the efficacy of SMER28 to promote health and slow ageing, as he was familiar with how studies in the nematode C. elegans could be translatable for drug discovery, and that Magnitude Biosciences had unique capabilities and a reputation for strong data reproducibility as led by CEO David Weinkove.
Findings
Magnitude Biosciences revealed SMER28 showed toxicity at relatively low concentrations, but using their unique Automated Imaging Platform, they found a range of concentrations with a robust positive effect on Healthspan. Establishing a dose response of SMER28 also demonstrated the sensitivity of Magnitude’s technology to identify tight therapeutic windows of compound concentrations that slow ageing.
Perspective
Excitingly, the target of SMER28 was recently identified by Wrobel et al (2022) in human cells as VCP (p97). This target is well conserved in C. elegans. The ****logue CDC-48.1 has 80% identity with the human protein, opening up an exciting opportunity to further study SMER28 in vivo to determine the mechanism for slowing ageing. The C. elegans cdc-48.1 mutant can be used to validate the target, determine if the toxicity remains in the absence of the target, and if so, ID any off-target effect. This work would provide a platform to discover new molecules that would be derivatives of SMER28 that hit the desired target to slow ageing but avoid the toxicity. This new safe molecule could be used to develop therapeutics to slow ageing in humans.
2x 750,000 just through. False drop don’t be fooled into selling your shares. They’re getting desperate
Bots? I genuinely think the sp is being manipulated to fill these big orders. Hopeing people sell when they see red. My buys showing red today. All games
Money, big pharma taking a position?
Again someone is loading up here. 2x2m a few weeks ago and now this today. Good times ahead.
GLA
Have been thinking about the new patent application plus the other one already submitted earlier in the year. I know these need approval and I’m sure they will get approved going off the company video on proactive. Company has stated doing everything in the correct manner, no short cuts. Surely even at this stage Genflow must be seen as a huge takeover option for big pharma. There’s far too much going on here for it not to be.
When the patents get approved this will propel the company even further away from competitors.
Just my thoughts. Would be really good to hear other people’s off the board too.
GLA
Nice to see more articles appearing now
UK-based biotech submits patent for transformational treatment of non-alcoholic fatty liver disease (NAFLD).
Genflow has announced that it has filed a new patent application with the US Patent and Trademark Office that relates to variants of Sirtuin-6, and the gene variant’s therapeutic uses for the treatment of two disorders involving the liver: non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), an advanced form of NAFLD.
Genflow holds the exclusive licence for this application through Genflow Biosciences, the company’s Belgian subsidiary.
Longevity.Technology: Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of individuals who do not consume excessive amounts of alcohol. A common disorder, it is estimated to affect up to 25% of the global population, and it is often associated with obesity, insulin resistance and type 2 diabetes. Although the exact causes of NAFLD are not fully understood, it is thought that the accumulation of fat in the liver may be due to a combination of factors, including aging, diet and genetics.
NAFLD can progress to more severe liver conditions, such as non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis – which can lead to liver failure and death. Research into NAFLD is key because in understanding the causes and mechanisms of the disease, science can develop effective treatments and preventions. As obesity rates in developed nations continue to climb, so the number of people with NASH, is expected to rise dramatically. In the past decade, large drug-makers including Allergan, Gilead and Novartis have spent billions of dollars acquiring or licensing medicines designed to treat NASH.
Sirtuins are a family of proteins that play important roles in regulating gene expression, metabolism, and stress resistance in the body. Involved in many cellular processes, including DNA repair, inflammation and cell survival, sirtuins are activated by the presence of certain molecules, such as NAD+ and sirtuin-activating compounds. They are found in all organisms, from bacteria to humans, and are thought to play a role in the health and lifespan of organisms; indeed research suggests that sirtuins may be involved in the aging process and may have potential as therapeutic targets for age-related diseases.
Lile, nice post.
Do we have any idea how long the patent process takes. 14 months?